Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine

Charalambos D. Partidos, Joanna Paykel, James Weger, Erin M. Borland, Ann M. Powers, Robert Seymour, Scott C. Weaver, Dan T. Stinchcomb, Jorge E. Osorio

Research output: Contribution to journalArticle

50 Scopus citations

Abstract

Emerging mosquito-borne alphavirus infections caused by chikungunya virus (CHIKV) or o'nyong-nyong virus (ONNV) are responsible for sporadic and sometimes explosive urban outbreaks. Currently, there is no licensed vaccine against either virus. We have developed a highly attenuated recombinant CHIKV candidate vaccine (CHIKV/IRES) that in preclinical studies was demonstrated to be safe, immunogenic and efficacious. In this study we investigated the potential of this vaccine to induce cross-protective immunity against the antigenically related ONNV. Our studies demonstrated that a single dose of CHIKV/IRES elicited a strong cross-neutralizing antibody response and conferred protection against ONNV challenge in the A129 mouse model. Moreover, CHIKV/IRES immune A129 dams transferred antibodies to their offspring that were protective, and passively transferred anti-CHIKV/IRES immune serum protected AG129 mice, independently of a functional IFN response. These findings highlight the potential of the CHIKV/IRES vaccine to protect humans against not only CHIKV but also against ONNV-induced disease.

Original languageEnglish (US)
Pages (from-to)4638-4643
Number of pages6
JournalVaccine
Volume30
Issue number31
DOIs
StatePublished - Jun 29 2012

Keywords

  • A129 mice
  • Chikungunya virus (CHIKV)
  • Interferon (IFN)
  • Maternal-fetal immunity
  • O'nyong-nyong virus (ONNV)

ASJC Scopus subject areas

  • Molecular Medicine
  • Immunology and Microbiology(all)
  • veterinary(all)
  • Public Health, Environmental and Occupational Health
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine'. Together they form a unique fingerprint.

  • Cite this

    Partidos, C. D., Paykel, J., Weger, J., Borland, E. M., Powers, A. M., Seymour, R., Weaver, S. C., Stinchcomb, D. T., & Osorio, J. E. (2012). Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine, 30(31), 4638-4643. https://doi.org/10.1016/j.vaccine.2012.04.099